Mark co-founded Inhibrx with Brendan Eckelman and Quinn Deveraux in 2010 and has served as its Chief Executive Officer and Chief Financial Officer since the company’s inception. Mark also serves as the Chairman of Inhibrx’s Board of Directors. Mark has extensive expertise in the biotechnology industry with over thirty years of experience in executive management, investment management and executive recruiting, having built the executive teams of over forty start-up biotechnology and medical device companies. Prior to founding Inhibrx, Mark was the founder and Managing Partner of Efficacy Biotech Fund, a fund focused on strategic investment in public biotechnology companies.
Dr. Kayyem is the founder of GenMark Diagnostics, Inc. (NASDAQ: GNMK) and is currently a consultant to GenMark’s Management and Board of Directors and participates as the Founder Observer on the GenMark Board of Directors. From May 2010 until February 2018, Dr. Kayyem served in various leadership positions at GenMark Diagnostics, Inc. including Senior Vice President of Research and Development, Chief Scientific Officer, President and Chief Executive Officer as the company evolved from Osmetech plc. In 2006, Dr. Kayyem founded and served as a member of the Board of Directors of privately held Calimmune Inc. until its acquisition by CSL Behring in 2017. In 1995, Dr. Kayyem founded Clinical Micro Sensors, Inc. to commercialize technical innovations he developed while serving as a Senior Research Fellow at The California Institute of Technology, or Caltech. In 2000, Clinical Micro Sensors, Inc. was sold to Motorola, Inc., and was subsequently purchased by Osmetech plc in 2005. From June 2000 until Dcember 2004, Dr. Kayyem served as Vice President of Life Sciences at Motorola, Inc. In October 2004, Dr. Kayyem co-founded the biotechnology fund management company, Efficacy Capital Limited, and, until September 2009, served as a managing partner. Dr. Kayyem received a combined Masters of Science and Bachelor of Science in Molecular Biophysics and Biochemistry from Yale University and a Ph.D. in Molecular Biology from Caltech.
Ms. Fischbein is currently Managing Director and Head of Healthcare Investment Banking with Seaport Global Securities, a private investment banking firm. From September 2014 until June 2017, Ms. Fischbein was Group Head of Healthcare Investment Banking with FBR & Co., a public investment bank. Previously, from March 2011 through August 2014, she was Managing Director and head of east coast biotechnology investment banking for JMP Securities, a public invesment banking firm. Margery has also worked in the biotechnology industry holding senior business and corporate development, strategy and alliance management positions with ImClone Systems, a large public oncology company, and Human Genome Sciences, a pioneering genomics company. Margery started her career at Lehman Brothers, JP Morgan Chase and Citigroup, and was a Managing Director in investment banking at both JP Morgan Chase and Citigroup.
Margery currently sits on the Board of Cytodel Inc., a private biotechnology company, and EcoHealth Alliance, a global non-profit leading scientific research into the critical connections between human, animal and environmental health. Ms Fischbein received a Bachelor of Arts in Economics from Harvard University and a Masters of Business Administration from Harvard Business School.
Ms. Li is a partner at Lilly Asia Ventures, or LAV, which is based in Hong Kong and Shanghai and focuses on early and growth stage investments across biopharmaceuticals, medical devices, and diagnostics both domestically and cross-border, since Nov 2013. Judith currently holds board appointments at a variety of LAV’s private portfolio companies, including Gritstone Oncology (GRTS), Just Biotherapeutics, Inc. and Nextcure, Inc. From April 2014 to October 2017, she served on the board of directors of Crown BioScience Inc., a biotechnology company which was publicly listed on the Taiwan Stock Exchange until it was acquired in December 2017. Previously, Ms. Li served as a senior business analyst at McKinsey & Company, worked in hospital administration at Partners Healthcare, and co-founded an interventional nephrology medical device venture. Ms. Li received a Bachelor of Arts in Biology from Harvard University and a Masters of Business Administration from Harvard Business School.
Mr. Forsyth has served since 1994 as a portfolio manager, a managing director and Chief Investment Officer Income & Growth Strategies with Allianz Global Investors, or Allianz. Mr. Forsyth is the head of the Allianz Income and Growth Strategies team and a member of the its US Executive Committee. Mr. Forsyth has portfolio management, trading and research responsibilities, and oversees all aspects of the Income and Growth platform’s business, including product development and implementation. He has been the lead portfolio manager for the Allianz High Yield Bond strategy since its inception in August 1994 and assumed lead portfolio management responsibility for the firm’s Convertible strategy in 1998. In addition to management responsibility for institutional clients worldwide, Mr. Forsyth supervises multiple open-end and closed-end mutual funds. Mr. Forsyth has 24 years of investment-industry experience. Mr. Forsyth has served as a director on several boards and currently serves as a member of the board of directors of Live Style, a leading international music event producer, and Ticket Sauce, an event management solutions software company. Mr. Forsyth received a Bachelor of Business Administration from the University of Iowa.
Brendan is a co-founder of Inhibrx and serves as its Chief Scientific Officer and Executive Vice President of Corporate Strategy. Brendan heads research, overseeing several key functional areas spanning discovery to therapeutic development. Brendan is also a member of Inhibrx’s Board of Directors. In addition, he has critical responsibilities in corporate strategy and operations. Prior to founding Inhibrx, he was a Research Investigator in the biotherapeutics group at the Genomics Institute of the Novartis Research Foundation (GNF). He conducted his graduate research at the Sanford-Burnham-Prebys Medical Discovery Institute. Brendan received his Ph.D. in molecular pathology from the University of California, San Diego School of Medicine.